An underutilized tool

Vaccination is an underutilized tool in the fight against antimicrobial resistance. By preventing infections, vaccines reduce the need for antibiotic use and limit the emergence of resistance.

Proven benefits, expanding pipeline

Vaccines against pathogens such as Streptococcus pneumoniae and Haemophilus influenzae have demonstrated significant public health benefits. Ongoing research aims to develop vaccines targeting resistant Gram-negative bacteria.

Integration with AMR strategy

Integrating vaccination strategies into AMR control programs offers a proactive approach to reducing disease burden.

Faster answers, targeted therapy

Rapid diagnostic tests are transforming clinical decision-making by reducing the time required to identify pathogens and resistance profiles. These tools enable earlier initiation of targeted therapy and reduce reliance on broad-spectrum antibiotics.

Integration with clinical judgment

Technologies such as multiplex PCR and point-of-care testing are increasingly integrated into clinical workflows. However, their effectiveness depends on appropriate interpretation and integration with clinical judgment.

Training unlocks the benefit

Training and guidelines are essential to maximize the benefits of these technologies.

Balancing patient and public health

The use of antimicrobials raises important ethical considerations, particularly in the context of resistance. Prescribing decisions must balance individual patient needs with broader public health implications.

A duty to prescribe judiciously

Overuse and misuse of antibiotics compromise their effectiveness for future patients. Clinicians have a responsibility to prescribe judiciously, guided by evidence and stewardship principles.

Frameworks for responsible practice

Ethical frameworks in antimicrobial use emphasize responsibility, equity, and sustainability. These principles should guide both clinical practice and policy development.

A vital component of development

Mentorship is a vital component of academic and professional development. Throughout my career, I have had the privilege of mentoring students and early-career researchers, observing firsthand the transformative impact of effective guidance.

More than technical expertise

A good mentor provides more than technical expertise. They foster critical thinking, encourage intellectual curiosity, and model ethical behavior. Importantly, mentorship should be tailored to the individual, recognizing that each mentee has unique strengths and aspirations.

The mentee's role

For mentees, active engagement is essential. They must be willing to seek feedback, embrace challenges, and continuously refine their skills. Strong mentorship relationships not only enhance individual careers but also contribute to the advancement of the field as a whole.

A heavier burden, fewer resources

In resource-limited settings, the burden of infectious diseases is often exacerbated by inadequate infrastructure and limited access to diagnostics and therapeutics. Despite these challenges, effective infection prevention is achievable through simple, cost-effective measures.

Simple measures, outsized impact

Hand hygiene remains the single most important intervention. Consistent use of alcohol-based hand rubs or soap and water can significantly reduce the transmission of pathogens. Environmental cleaning, proper waste disposal, and rational antibiotic use further contribute to infection control.

Education sustains the gains

My experience has shown that education and training are critical. Healthcare workers must be equipped with the knowledge and tools to implement these measures consistently. Even in constrained environments, sustained commitment to basic principles can yield substantial improvements.

A slow but hopeful pipeline

The development of new antimicrobial agents has been relatively slow compared to the pace of resistance. Nevertheless, recent advances offer cautious optimism. Novel beta-lactam/beta-lactamase inhibitor combinations have demonstrated efficacy against certain resistant organisms, while alternative approaches such as bacteriophage therapy are gaining renewed interest.

Stewardship determines longevity

These therapies represent important additions to our therapeutic arsenal. However, their long-term effectiveness depends on judicious use. Overuse or misuse will inevitably lead to the emergence of resistance, repeating the cycle observed with earlier antibiotics.

Research and collaboration

Ongoing research, including clinical trials and real-world studies, is essential to evaluate the safety, efficacy, and optimal use of these therapies. Collaboration between academia, industry, and regulatory bodies will be key to sustaining progress in this field.

Fundamental to credibility

Data integrity is fundamental to scientific credibility. In clinical microbiology, this encompasses accurate organism identification, standardized susceptibility testing, and meticulous documentation.

When errors propagate

Errors in data collection or analysis can have far-reaching consequences, including flawed conclusions and compromised patient care. For example, misidentification of a resistant organism may lead to inappropriate therapy, with potentially serious outcomes.

Standards and transparency

To ensure data integrity, laboratories must adhere to standardized protocols and participate in quality assurance programs. Researchers should also adopt transparent reporting practices, enabling reproducibility and peer verification. Ultimately, maintaining high standards of data integrity is essential for advancing knowledge and improving clinical outcomes.

Art and discipline

Scientific writing is both an art and a discipline. Over the course of my career, I have reviewed and authored numerous manuscripts, observing that the most impactful papers share common characteristics: clarity, structure, and precision.

Structure that serves the reader

Effective writing begins with a clear research question and a logical study design. The manuscript should present data in a coherent manner, avoiding unnecessary complexity or redundancy. Each section — introduction, methods, results, and discussion — must serve a distinct purpose and contribute to the overall narrative.

Guidelines and audience

Equally important is adherence to journal guidelines. Failure to comply with formatting or referencing requirements can delay publication or result in rejection. Authors should also be mindful of their audience, ensuring that their work is accessible to both specialists and the broader scientific community.

A profound transformation

The field of diagnostic microbiology has undergone a profound transformation with the advent of molecular technologies. Techniques such as polymerase chain reaction (PCR), multiplex assays, and whole-genome sequencing now allow rapid and precise identification of pathogens and resistance genes.

Speed and its limits

These advancements have significantly reduced the time to diagnosis, enabling earlier initiation of targeted therapy. In critical care settings, where time is often a decisive factor, such improvements can be life-saving. However, molecular methods are not without limitations. They may detect genetic material from non-viable organisms or fail to provide information on phenotypic susceptibility.

A balanced approach

Therefore, a balanced approach is essential. Molecular diagnostics should complement, rather than replace, conventional culture-based methods. Together, they provide a comprehensive understanding of infectious processes and guide optimal patient management.

A central pillar

Antimicrobial stewardship has evolved into a central pillar of modern healthcare. Its primary objective is to optimize antibiotic use to achieve the best clinical outcomes while minimizing unintended consequences such as resistance, toxicity, and cost.

A multidisciplinary effort

Effective stewardship programs are inherently multidisciplinary. They require the collaboration of clinicians, microbiologists, pharmacists, and infection control specialists. Key strategies include formulary restriction, prospective audit and feedback, and guideline development. Education also plays a vital role, ensuring that healthcare providers understand the principles of rational antibiotic use.

Supportive, not restrictive

Importantly, stewardship should not be perceived as restrictive but as supportive. By providing clinicians with evidence-based guidance and real-time data, stewardship programs enhance clinical decision-making and improve patient care.

Why surveillance matters

Surveillance is the cornerstone of effective infection prevention and control. Without accurate and timely data, it is impossible to understand the dynamics of infectious diseases or to implement appropriate interventions.

Integrated systems

Over the years, I have advocated for integrated surveillance systems that combine microbiological data with clinical and epidemiological information. Such systems enable healthcare institutions to detect outbreaks early, monitor resistance trends, and evaluate the impact of interventions. Importantly, surveillance data inform empirical treatment guidelines, ensuring that patients receive the most appropriate therapy from the outset.

Data quality and collaboration

Modern surveillance increasingly relies on digital tools and data analytics. However, the success of these systems depends on the quality of the underlying data. Standardization of laboratory methods, consistent reporting, and interdisciplinary collaboration are critical components of a robust surveillance framework.

A persistent challenge

Gram-negative bacteria continue to pose a significant clinical challenge due to their structural complexity and remarkable ability to acquire resistance determinants. Their outer membrane acts as a barrier to many antibiotics, while their genetic flexibility enables rapid adaptation under selective pressure.

Clinical impact

In clinical practice, infections caused by multidrug-resistant Gram-negative organisms are associated with increased morbidity, mortality, and healthcare costs. Common scenarios include bloodstream infections, ventilator-associated pneumonia, and complicated urinary tract infections. These infections often require prolonged hospitalization and the use of toxic or less effective therapeutic alternatives.

Management principles

Effective management depends on timely and accurate microbiological diagnosis. Empirical therapy should be guided by local epidemiological data, with prompt de-escalation based on susceptibility results. In addition, infection prevention strategies — such as strict adherence to hygiene protocols — are essential to limit transmission within healthcare settings.

A crisis in motion

Antimicrobial resistance (AMR) has transitioned from a theoretical concern to an immediate and escalating global health crisis. Over the past three decades, I have witnessed a troubling acceleration in the emergence and dissemination of resistant organisms, particularly among Gram-negative bacteria. Pathogens such as Klebsiella pneumoniae, Escherichia coli, and Acinetobacter baumannii now frequently exhibit resistance to multiple antibiotic classes, including last-resort agents like carbapenems.

Mechanisms of resistance

The mechanisms underlying this resistance are both diverse and highly adaptive. Extended-spectrum beta-lactamases (ESBLs), carbapenemases such as KPC and NDM, and efflux pumps collectively contribute to therapeutic failure. Compounding this problem is the horizontal transfer of resistance genes via plasmids, which facilitates rapid spread across bacterial populations and geographical regions.

A coordinated response

Addressing AMR requires a multifaceted approach. Surveillance systems must be strengthened to provide real-time data on resistance trends. Clinicians must adopt evidence-based prescribing practices, avoiding unnecessary or inappropriate antibiotic use. Equally important is sustained investment in research and development of new antimicrobial agents. Without coordinated global action, the gains of modern medicine risk being undermined.

Introduction

Spinal muscular atrophy (SMA) has undergone one of the most dramatic transformations in modern medicine. Once considered a leading genetic cause of infant mortality, SMA is now at the forefront of precision therapeutics, driven by advances in gene therapy and RNA-targeted interventions. This shift has not only altered clinical outcomes but has also redefined expectations for rare disease treatment.

Disease mechanism and genetic basis

SMA is caused by mutations or deletions in the SMN1 gene, resulting in insufficient production of survival motor neuron (SMN) protein. This deficiency leads to progressive degeneration of motor neurons in the spinal cord, ultimately impairing voluntary muscle movement.

Humans possess a paralog gene, SMN2, which produces limited functional SMN protein due to alternative splicing. The number of SMN2 copies partially influences disease severity, providing a therapeutic target for intervention.

Therapeutic breakthroughs

Recent years have seen the emergence of disease-modifying therapies that directly target the underlying genetic defect:

• Gene replacement therapy delivers a functional copy of SMN1 via viral vectors, offering long-term benefit from a single administration.
• Splicing modifiers enhance the inclusion of exon 7 in SMN2 transcripts, increasing production of functional SMN protein.

These approaches have demonstrated unprecedented clinical benefits, including improved survival, attainment of motor milestones, and reduced need for ventilatory support.

Importance of early intervention

Clinical evidence consistently highlights the critical importance of early treatment. Presymptomatic infants identified through newborn screening programmes exhibit significantly better outcomes than those treated after symptom onset.

This has led to widespread implementation of newborn screening for SMA, enabling early diagnosis and timely intervention. The paradigm has shifted from reactive treatment to proactive disease management.

Real-world evidence and long-term outcomes

While clinical trials have established efficacy, real-world data are essential to understand long-term outcomes. Patient registries and observational studies are providing valuable insights into:

• Durability of therapeutic effects
• Long-term safety profiles
• Functional outcomes over time

Questions remain regarding whether early gains can be sustained into adolescence and adulthood.

Challenges and unresolved questions

• Durability of gene therapy. Tissue growth, vector persistence, and immune responses may all influence long-term efficacy of a so-called one-time treatment.
• Treatment sequencing. With multiple options available, the optimal sequence or combination strategy is still being defined.
• Access and cost. High therapy prices create significant barriers, particularly in low- and middle-income countries.

The role of medical communications

As the SMA landscape evolves, translating complex clinical data into clear, actionable insight is essential for clinicians making treatment decisions, regulators evaluating therapies, and patients and caregivers weighing options. Effective communication is what turns scientific advances into real-world impact.

Future directions

The next phase of SMA research is focused on redosing strategies for gene therapy, next-generation vectors, and biomarkers to monitor treatment response — all aimed at refining therapy and improving long-term outcomes.

Conclusion

SMA has transitioned from a fatal paediatric condition to a manageable disease with transformative therapeutic options. While challenges remain, the progress achieved underscores the potential of precision medicine to reshape the future of rare disease treatment.

Introduction

Sickle cell disease (SCD) has long been a paradigm of unmet medical need, characterised by chronic pain, organ damage, and reduced life expectancy. Recent advances in gene editing — particularly CRISPR-based approaches — have introduced the possibility of a functional cure.

Pathophysiology

SCD is caused by a single nucleotide mutation in the β-globin gene, producing abnormal haemoglobin (HbS). Under low oxygen conditions, HbS polymerises and red blood cells adopt a sickle shape, leading to:

• Vaso-occlusion
• Chronic haemolysis
• Inflammation and organ damage

Evolution of treatment

Traditional management has focused on symptom control and prevention of complications, including hydroxyurea therapy, blood transfusions, and supportive care. While effective in reducing morbidity, these approaches do not address the underlying genetic defect.

Gene therapy and gene editing

Recent developments have transformed the treatment landscape:

• Gene addition therapies introduce functional copies of the β-globin gene.
• Gene editing approaches modify haematopoietic stem cells to increase fetal haemoglobin production.

CRISPR-based therapies have demonstrated promising results in early clinical trials, with patients achieving sustained increases in haemoglobin and reduced vaso-occlusive events.

Clinical and ethical considerations

• Long-term safety. Gene editing is relatively new; off-target effects and unintended genetic changes remain key concerns.
• Accessibility. Therapies are complex and costly, requiring specialised infrastructure that limits equitable access.
• Ethical implications. Editing the human genome raises lasting questions about long-term consequences and societal impact.

Real-world implementation challenges

Scaling gene therapies from clinical trials to routine practice involves overcoming logistical barriers, including manufacturing capacity, patient eligibility criteria, and healthcare system readiness.

Future outlook

Ongoing research aims to improve safety and efficiency of gene editing, develop less invasive delivery methods, and expand access to broader patient populations.

Conclusion

SCD is entering a new era of treatment, with gene editing offering unprecedented potential. Translating that promise into widespread clinical benefit will require addressing significant scientific, logistical, and ethical challenges in parallel.

Introduction

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating neurodegenerative diseases, characterised by progressive loss of motor neurons and eventual respiratory failure. Despite decades of research, therapeutic progress has been incremental.

Disease biology

ALS involves degeneration of upper and lower motor neurons, leading to muscle weakness, paralysis, and death. The disease is heterogeneous, with both genetic and sporadic forms. Key mechanisms include:

• Protein aggregation
• Oxidative stress
• Neuroinflammation

Current treatment landscape

Approved therapies provide modest benefits, primarily slowing disease progression rather than reversing it. The need for more effective treatments remains urgent.

Emerging therapeutic approaches

RNA-based therapies. By targeting specific genetic mutations, RNA therapies aim to reduce production of toxic proteins, marking a shift toward personalised medicine.

Biomarker development. Identifying reliable biomarkers is critical for early diagnosis and for monitoring treatment response.

Clinical trial challenges

ALS trials face unique challenges that complicate design and interpretation:

• Small patient populations
• Rapid disease progression
• Heterogeneity in disease presentation

Role of real-world evidence

Real-world data are increasingly used to complement clinical trials, providing insight into disease progression and long-term treatment outcomes that controlled studies alone cannot capture.

Future directions

Research efforts are focused on combination therapies, earlier intervention strategies, and improved trial designs that better match the realities of ALS biology.

Conclusion

While progress in ALS has been slower than in other rare diseases, ongoing research offers hope. Continued innovation and collaboration will be essential to achieve meaningful breakthroughs for patients and families.